WuXi Biologics (Cayman) (2269) Fundamentals 2026 — P/E 28.2x, Revenue Analysis | SniperIQ
WuXi Biologics (Cayman) (2269) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK
8.84 on the HKSE. This SniperIQ fundamentals page covers WuXi Biologics (Cayman)'s valuation (P/E 28.2x, P/B 3.0x), profitability (net margin 22.5%), revenue (¥21.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is WuXi Biologics (Cayman)'s market cap?
WuXi Biologics (Cayman) (2269) has a market capitalization of approximately HK
8.84 on the HKSE. Market cap moves with the live share price.What is WuXi Biologics (Cayman)'s P/E ratio?
WuXi Biologics (Cayman)'s trailing twelve-month P/E ratio is 28.2x, with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is WuXi Biologics (Cayman)?
WuXi Biologics (Cayman) runs a net profit margin of 22.5%, a gross margin of 46.0%, and an operating margin of 30.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does WuXi Biologics (Cayman) generate?
WuXi Biologics (Cayman) reported revenue of ¥21.8B for fiscal year 2025, with net income of ¥4.9B and earnings per share (EPS) of 1.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does WuXi Biologics (Cayman) pay a dividend?
WuXi Biologics (Cayman) does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is WuXi Biologics (Cayman) financially healthy?
WuXi Biologics (Cayman) carries a debt-to-equity ratio of 0.07x and a current ratio of 3.14x, with a market beta of 0.58. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is WuXi Biologics (Cayman) a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For WuXi Biologics (Cayman) (2269) the key facts are: market cap HK
Track WuXi Biologics (Cayman)'s full fundamentals live
Get WuXi Biologics (Cayman)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.